BI 137882

Drug Profile

BI 137882

Latest Information Update: 16 Apr 2013

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Chronic obstructive pulmonary disease

Most Recent Events

  • 27 Feb 2013 Boehringer Ingelheim terminates its phase I trial in healthy volunteers in Germany (NCT01348165)
  • 23 Aug 2011 Suspended - Phase-I for Chronic obstructive pulmonary disease in Germany (PO)
  • 31 May 2011 Phase-I clinical trials in Chronic obstructive pulmonary disease (in volunteers) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top